Literature DB >> 4187132

Survival studies on a commercial preparation of intravenous human gammaglobulin labelled with 131-I.

J V Wells, R Penny.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4187132     DOI: 10.1111/imj.1969.18.3.271

Source DB:  PubMed          Journal:  Australas Ann Med        ISSN: 0571-9283


× No keyword cloud information.
  7 in total

1.  Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency.

Authors:  R I Schiff; C Rudd
Journal:  J Clin Immunol       Date:  1986-05       Impact factor: 8.317

2.  Metabolism of radio-iodinated IgG in patients with abnormal serum IgG levels. II. Hypogamma-globulinaemia.

Authors:  J V Wells; H H Fudenberg
Journal:  Clin Exp Immunol       Date:  1971-12       Impact factor: 4.330

3.  Metabolism of radio-iodinated IgG in patients with abnormal IgG levels. I. Hypergamma-globulinaemia.

Authors:  J V Wells; H H Fudenberg
Journal:  Clin Exp Immunol       Date:  1971-12       Impact factor: 4.330

4.  Half-life of the maternal IgG1 allotype in infants.

Authors:  H Sarvas; I Seppälä; S Kurikka; R Siegberg; O Mäkelä
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

Review 5.  [Therapeutic use of immunoglobulins in children (author's transl)].

Authors:  W H Hitzig
Journal:  Blut       Date:  1980-03

6.  [Tolerance of a new intravenously applied immunoglobulin preparation and its effect on serum globulin levels].

Authors:  W Hansi; H Heimpel; S Barandun; O Lutz
Journal:  Infection       Date:  1982 Nov-Dec       Impact factor: 3.553

7.  Intravenous immunoglobulin therapy for antibody deficiency.

Authors:  M T Nolte; B Pirofsky; G A Gerritz; B Golding
Journal:  Clin Exp Immunol       Date:  1979-05       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.